The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2β and agonist-independent coupling with downstream signalling events
The EGFR (epidermal growth factor receptor; ErbB1) is frequently the subject of genetic changes in human tumours which contribute to the malignant phenotype by altering EGFR signalling. Examples of such genetic changes include overexpression, extracellular domain deletions and point mutations, and s...
Saved in:
Published in | Biochemical journal Vol. 396; no. 1; pp. 79 - 88 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Portland Press Ltd
15.05.2006
|
Online Access | Get full text |
Cover
Loading…
Abstract | The EGFR (epidermal growth factor receptor; ErbB1) is frequently the subject of genetic changes in human tumours which contribute to the malignant phenotype by altering EGFR signalling. Examples of such genetic changes include overexpression, extracellular domain deletions and point mutations, and small deletions in the tyrosine kinase domain. We hypothesized that a point mutation in one of the EGFR ligand-binding domains would increase the affinity of EGFR for NRG2β (neuregulin-2β), which is not a potent stimulus of signalling by EGFR-Wt (wild-type EGFR). This mutation would permit NRG2β stimulation of EGFR signalling in settings in which NRG2β does not normally do so. To test this hypothesis, we have generated and evaluated various EGFR alleles containing mutations at Val441 and Ser442. NRG2β is a much more potent stimulus of the EGFR-S442F mutant than of EGFR-Wt. Furthermore, the affinity of NRG2β for the EGFR-S442F mutant is greater than the affinity of NRG2β for EGFR-Wt. Finally, the EGFR-S442F mutant constitutively suppresses apoptosis via phosphoinositide 3-kinase and Akt signalling but is not highly tyrosine phosphorylated in the absence of ligand. These results suggest that mutations in the EGFR ligand-binding domain in tumours may permit potent stimulation of EGFR signalling by ligands that are not normally potent EGFR agonists, thereby providing for a novel mechanism by which EGFR signalling may be deregulated. These results also suggest that novel EGFR mutations and signalling activities may be responsible for deregulated EGFR signalling in tumour cells. |
---|---|
AbstractList | The EGFR (epidermal growth factor receptor; ErbB1) is frequently the subject of genetic changes in human tumours which contribute to the malignant phenotype by altering EGFR signalling. Examples of such genetic changes include overexpression, extracellular domain deletions and point mutations, and small deletions in the tyrosine kinase domain. We hypothesized that a point mutation in one of the EGFR ligand-binding domains would increase the affinity of EGFR for NRG2β (neuregulin-2β), which is not a potent stimulus of signalling by EGFR-Wt (wild-type EGFR). This mutation would permit NRG2β stimulation of EGFR signalling in settings in which NRG2β does not normally do so. To test this hypothesis, we have generated and evaluated various EGFR alleles containing mutations at Val441 and Ser442. NRG2β is a much more potent stimulus of the EGFR-S442F mutant than of EGFR-Wt. Furthermore, the affinity of NRG2β for the EGFR-S442F mutant is greater than the affinity of NRG2β for EGFR-Wt. Finally, the EGFR-S442F mutant constitutively suppresses apoptosis via phosphoinositide 3-kinase and Akt signalling but is not highly tyrosine phosphorylated in the absence of ligand. These results suggest that mutations in the EGFR ligand-binding domain in tumours may permit potent stimulation of EGFR signalling by ligands that are not normally potent EGFR agonists, thereby providing for a novel mechanism by which EGFR signalling may be deregulated. These results also suggest that novel EGFR mutations and signalling activities may be responsible for deregulated EGFR signalling in tumour cells. The EGFR (epidermal growth factor receptor; ErbB1) is frequently the subject of genetic changes in human tumours which contribute to the malignant phenotype by altering EGFR signalling. Examples of such genetic changes include overexpression, extracellular domain deletions and point mutations, and small deletions in the tyrosine kinase domain. We hypothesized that a point mutation in one of the EGFR ligand-binding domains would increase the affinity of EGFR for NRG2β (neuregulin-2β), which is not a potent stimulus of signalling by EGFR-Wt (wild-type EGFR). This mutation would permit NRG2β stimulation of EGFR signalling in settings in which NRG2β does not normally do so. To test this hypothesis, we have generated and evaluated various EGFR alleles containing mutations at Val 441 and Ser 442 . NRG2β is a much more potent stimulus of the EGFR-S442F mutant than of EGFR-Wt. Furthermore, the affinity of NRG2β for the EGFR-S442F mutant is greater than the affinity of NRG2β for EGFR-Wt. Finally, the EGFR-S442F mutant constitutively suppresses apoptosis via phosphoinositide 3-kinase and Akt signalling but is not highly tyrosine phosphorylated in the absence of ligand. These results suggest that mutations in the EGFR ligand-binding domain in tumours may permit potent stimulation of EGFR signalling by ligands that are not normally potent EGFR agonists, thereby providing for a novel mechanism by which EGFR signalling may be deregulated. These results also suggest that novel EGFR mutations and signalling activities may be responsible for deregulated EGFR signalling in tumour cells. |
Author | Gilmore, Jennifer L. Gallo, Richard M. Riese, David J. |
Author_xml | – sequence: 1 givenname: Jennifer L. surname: Gilmore fullname: Gilmore, Jennifer L. organization: Purdue University School of Pharmacy and Purdue Cancer Research Center, Purdue University, West Lafayette, IN 47907-2064, U.S.A – sequence: 2 givenname: Richard M. surname: Gallo fullname: Gallo, Richard M. organization: Purdue University School of Pharmacy and Purdue Cancer Research Center, Purdue University, West Lafayette, IN 47907-2064, U.S.A – sequence: 3 givenname: David J. surname: Riese fullname: Riese, David J. organization: Purdue University School of Pharmacy and Purdue Cancer Research Center, Purdue University, West Lafayette, IN 47907-2064, U.S.A |
BookMark | eNpVkcFu1DAQhi1URLctF57AR0AKjB3H8V6QaNVtQZUqQXuOnHicNUrsyE662lfiyIPwTPVSBOplZqR__m-k-U_IkQ8eCXnD4AMDwT-ef-UAFZOqfkFWTNRQqJqrI7ICLkUhgbNjcpLSDwAmQMArcsykEFWpqhX5ebdFipMzGEc90D6G3bylVndziDRih9NheHt5tfn2rvguBN_QcZm1n6lxaRr0PlHnu4g6oaHaWufdvKc2ezwuEftlcL7gv39R7bPeB-_SXDhvcMJcMqYLy5R3erpz-bAJO5_mjBtpcr3Xwx8JH_JmOiMvrR4Svv7bT8n95vLu4rq4ub36cvH5puhKzudiDaBqyysG0lSd4m1t61Zbzphsq_wRJowtGbetXLdSaluthUKDuFZKtIrL8pR8euJOSzui6fLtqIdmim7Ucd8E7Zrninfbpg8PDRMVABwA758AXQwpRbT_vAyaQ2LN_8TKR1GPjcc |
CitedBy_id | crossref_primary_10_1134_S0006297920090011 crossref_primary_10_1016_j_pharmthera_2008_11_008 crossref_primary_10_1016_j_semcdb_2014_03_005 crossref_primary_10_1002_bies_20582 crossref_primary_10_1042_BJ20110921 crossref_primary_10_1016_j_cellsig_2008_10_003 crossref_primary_10_3109_08977194_2011_649918 crossref_primary_10_1124_pharmrev_121_000381 crossref_primary_10_2119_molmed_2008_00103 crossref_primary_10_1016_j_bbrc_2007_10_004 crossref_primary_10_1517_17460441_2011_547468 crossref_primary_10_1074_jbc_M110_107508 crossref_primary_10_1038_srep04242 |
Cites_doi | 10.1016/S0092-8674(02)00963-7 10.1038/sj.onc.1202499 10.1016/S0304-3835(02)00690-0 10.1126/science.1101637 10.1016/j.yexcr.2005.05.012 10.1073/pnas.91.21.10217 10.1073/pnas.94.21.11345 10.1016/S0898-6568(02)00019-0 10.1074/jbc.271.33.20047 10.1056/NEJMoa040938 10.1038/sj.onc.1203913 10.1128/MCB.18.10.6090 10.1128/MCB.18.9.5371 10.1016/S1097-2765(03)00047-9 10.1073/pnas.89.10.4309 10.1038/35052073 10.1038/sj.onc.1207250 10.1073/pnas.87.21.8602 10.1210/en.2004-0401 10.1038/sj.onc.1205960 10.1074/jbc.273.18.11288 10.1074/jbc.C901015199 10.1128/MCB.15.10.5770 10.1056/NEJMoa044238 10.1002/prot.20443 10.1021/jm050607w 10.1016/S0092-8674(02)00940-6 10.1158/1078-0432.600.11.2 10.1038/nrc1609 10.1080/08977190500199345 10.1073/pnas.0502860102 10.1038/sj.onc.1207257 |
ContentType | Journal Article |
Copyright | The Biochemical Society, London 2006 |
Copyright_xml | – notice: The Biochemical Society, London 2006 |
DBID | AAYXX CITATION 5PM |
DOI | 10.1042/BJ20051687 |
DatabaseName | CrossRef PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Chemistry |
DocumentTitleAlternate | Partial gain-of-function EGFR mutant |
EISSN | 1470-8728 |
EndPage | 88 |
ExternalDocumentID | 10_1042_BJ20051687 |
GroupedDBID | --- -DZ -~X .55 .GJ 0R~ 23N 2WC 3EH 3O- 4.4 53G 5GY 5RE 5VS 6J9 79B AABGO AAHRG AAYXX ABPPZ ABTAH ACGFO ACGFS ACNCT ADBBV AEGXH AENEX AI. AIAGR AIZAD ALMA_UNASSIGNED_HOLDINGS BAWUL CITATION CS3 DU5 E3Z EBS EJD F20 F5P H13 HH6 HYE HZ~ K-O L7B MV1 MVM N9A O9- OHT OK1 P2P RHI RNS RPM RPO TR2 TWZ VH1 WH7 WOQ X7M XSW Y6R YNY ZXP ZY4 ~02 ~KM 5PM |
ID | FETCH-LOGICAL-c322t-90087f25106d5c82b7f7baf2116b502614df312fb69b66af5948edee9884b8263 |
IEDL.DBID | RPM |
ISSN | 0264-6021 |
IngestDate | Tue Sep 17 20:29:41 EDT 2024 Fri Aug 23 01:25:35 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c322t-90087f25106d5c82b7f7baf2116b502614df312fb69b66af5948edee9884b8263 |
OpenAccessLink | https://europepmc.org/articles/pmc1450006?pdf=render |
PMID | 16445385 |
PageCount | 10 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_1450006 crossref_primary_10_1042_BJ20051687 |
PublicationCentury | 2000 |
PublicationDate | 2006-05-15 |
PublicationDateYYYYMMDD | 2006-05-15 |
PublicationDate_xml | – month: 05 year: 2006 text: 2006-05-15 day: 15 |
PublicationDecade | 2000 |
PublicationTitle | Biochemical journal |
PublicationYear | 2006 |
Publisher | Portland Press Ltd |
Publisher_xml | – name: Portland Press Ltd |
References | Williams (2021112213074206800_B19) 2003; 192 Chung (2021112213074206800_B35) 2005; 309 Hobbs (2021112213074206800_B14) 2005; 23 Sweeney (2021112213074206800_B32) 2000; 19 Saito (2021112213074206800_B34) 2004; 145 Ekstrand (2021112213074206800_B3) 1992; 89 Songyang (2021112213074206800_B27) 1997; 94 Burke (2021112213074206800_B30) 1998; 18 Yarden (2021112213074206800_B1) 2001; 2 Moriai (2021112213074206800_B28) 1994; 91 Wikstrand (2021112213074206800_B4) 1995; 55 Sordella (2021112213074206800_B7) 2004; 305 Lynch (2021112213074206800_B6) 2004; 350 Amin (2021112213074206800_B33) 2004; 23 Pinkas-Kramarski (2021112213074206800_B11) 1998; 18 Luo (2021112213074206800_B17) 2005; 59 Feroz (2021112213074206800_B20) 2002; 14 Kwak (2021112213074206800_B10) 2005; 102 Sugawa (2021112213074206800_B5) 1990; 87 Sweeney (2021112213074206800_B31) 2000; 275 Garrett (2021112213074206800_B15) 2002; 110 Kobayashi (2021112213074206800_B8) 2005; 352 VanBrocklin (2021112213074206800_B26) 2005; 48 Riese (2021112213074206800_B18) 1995; 15 Riese (2021112213074206800_B21) 1996; 271 Ettenberg (2021112213074206800_B25) 1999; 18 Pao (2021112213074206800_B9) 2005; 2 Hobbs (2021112213074206800_B12) 2002; 21 Ogiso (2021112213074206800_B16) 2002; 110 Hobbs (2021112213074206800_B13) 2004; 23 Ferguson (2021112213074206800_B23) 2003; 11 Riese (2021112213074206800_B22) 1996; 12 Zhang (2021112213074206800_B29) 2005; 11 Hynes (2021112213074206800_B2) 2005; 5 Riese (2021112213074206800_B24) 1998; 273 |
References_xml | – volume: 110 start-page: 775 year: 2002 ident: 2021112213074206800_B16 article-title: Crystal structure of the complex of human epidermal growth factor and receptor extracellular domain publication-title: Cell doi: 10.1016/S0092-8674(02)00963-7 contributor: fullname: Ogiso – volume: 18 start-page: 1855 year: 1999 ident: 2021112213074206800_B25 article-title: Cbl-b inhibits epidermal growth factor receptor signaling publication-title: Oncogene doi: 10.1038/sj.onc.1202499 contributor: fullname: Ettenberg – volume: 192 start-page: 67 year: 2003 ident: 2021112213074206800_B19 article-title: A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines publication-title: Cancer Lett. doi: 10.1016/S0304-3835(02)00690-0 contributor: fullname: Williams – volume: 305 start-page: 1163 year: 2004 ident: 2021112213074206800_B7 article-title: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways publication-title: Science doi: 10.1126/science.1101637 contributor: fullname: Sordella – volume: 309 start-page: 149 year: 2005 ident: 2021112213074206800_B35 article-title: Differential effects of amphiregulin and TGF-α on the morphology of MDCK cells publication-title: Exp. Cell Res. doi: 10.1016/j.yexcr.2005.05.012 contributor: fullname: Chung – volume: 91 start-page: 10217 year: 1994 ident: 2021112213074206800_B28 article-title: A variant epidermal growth factor receptor exhibits altered type α transforming growth factor α binding and transmembrane signaling publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.91.21.10217 contributor: fullname: Moriai – volume: 94 start-page: 11345 year: 1997 ident: 2021112213074206800_B27 article-title: Interleukin 3-dependent survival by the Akt protein kinase publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.94.21.11345 contributor: fullname: Songyang – volume: 14 start-page: 793 year: 2002 ident: 2021112213074206800_B20 article-title: ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation publication-title: Cell. Signalling doi: 10.1016/S0898-6568(02)00019-0 contributor: fullname: Feroz – volume: 271 start-page: 20047 year: 1996 ident: 2021112213074206800_B21 article-title: The epidermal growth factor receptor couples the transforming growth factor-α, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4 publication-title: J. Biol. Chem. doi: 10.1074/jbc.271.33.20047 contributor: fullname: Riese – volume: 350 start-page: 2129 year: 2004 ident: 2021112213074206800_B6 article-title: Activating mutations in the epidermal growth factor receptor underling responsiveness of non-small-cell lung cancer to Gefitinib publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa040938 contributor: fullname: Lynch – volume: 12 start-page: 345 year: 1996 ident: 2021112213074206800_B22 article-title: Betacellulin activates the epidermal growth factor receptor and erbB-4 and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-β publication-title: Oncogene contributor: fullname: Riese – volume: 19 start-page: 5568 year: 2000 ident: 2021112213074206800_B32 article-title: Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage publication-title: Oncogene doi: 10.1038/sj.onc.1203913 contributor: fullname: Sweeney – volume: 18 start-page: 6090 year: 1998 ident: 2021112213074206800_B11 article-title: ErbB tyrosine kinases and the two neuregulin families constitute a ligand–receptor network publication-title: Mol. Cell. Biol. doi: 10.1128/MCB.18.10.6090 contributor: fullname: Pinkas-Kramarski – volume: 18 start-page: 5371 year: 1998 ident: 2021112213074206800_B30 article-title: Activation of Neu (ErbB2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface publication-title: Mol. Cell. Biol. doi: 10.1128/MCB.18.9.5371 contributor: fullname: Burke – volume: 11 start-page: 507 year: 2003 ident: 2021112213074206800_B23 article-title: EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization publication-title: Mol. Cell doi: 10.1016/S1097-2765(03)00047-9 contributor: fullname: Ferguson – volume: 89 start-page: 4309 year: 1992 ident: 2021112213074206800_B3 article-title: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.89.10.4309 contributor: fullname: Ekstrand – volume: 2 start-page: 225 year: 2005 ident: 2021112213074206800_B9 article-title: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain publication-title: PLos Med. contributor: fullname: Pao – volume: 2 start-page: 127 year: 2001 ident: 2021112213074206800_B1 article-title: Untangling the ErbB signaling network publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/35052073 contributor: fullname: Yarden – volume: 23 start-page: 883 year: 2004 ident: 2021112213074206800_B13 article-title: Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase publication-title: Oncogene doi: 10.1038/sj.onc.1207250 contributor: fullname: Hobbs – volume: 87 start-page: 8602 year: 1990 ident: 2021112213074206800_B5 article-title: Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.87.21.8602 contributor: fullname: Sugawa – volume: 145 start-page: 4232 year: 2004 ident: 2021112213074206800_B34 article-title: Differential activation of epidermal growth factor (EGF) receptor downstream signaling pathways by betacellulin and EGF publication-title: Endocrinology doi: 10.1210/en.2004-0401 contributor: fullname: Saito – volume: 55 start-page: 3140 year: 1995 ident: 2021112213074206800_B4 article-title: Monoclonal antibodies against EGFRVIII are tumor specific and react with breast and lung carcinomas and malignant gliomas publication-title: Cancer Res. contributor: fullname: Wikstrand – volume: 21 start-page: 8442 year: 2002 ident: 2021112213074206800_B12 article-title: Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation publication-title: Oncogene doi: 10.1038/sj.onc.1205960 contributor: fullname: Hobbs – volume: 273 start-page: 11288 year: 1998 ident: 2021112213074206800_B24 article-title: Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2 publication-title: J. Biol. Chem. doi: 10.1074/jbc.273.18.11288 contributor: fullname: Riese – volume: 275 start-page: 19803 year: 2000 ident: 2021112213074206800_B31 article-title: Ligand discrimination in signaling through an ErbB4 receptor homodimer publication-title: J. Biol. Chem. doi: 10.1074/jbc.C901015199 contributor: fullname: Sweeney – volume: 15 start-page: 5770 year: 1995 ident: 2021112213074206800_B18 article-title: The cellular response to neuregulins is governed by complex interactions of the erbB receptor family publication-title: Mol. Cell. Biol. doi: 10.1128/MCB.15.10.5770 contributor: fullname: Riese – volume: 352 start-page: 786 year: 2005 ident: 2021112213074206800_B8 article-title: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa044238 contributor: fullname: Kobayashi – volume: 59 start-page: 749 year: 2005 ident: 2021112213074206800_B17 article-title: Computational analysis of molecular basis of 1:1 interactions of NRG1β wild-type and variants with ErbB3 and ErbB4 publication-title: Proteins Struct. Funct. Bioinform. doi: 10.1002/prot.20443 contributor: fullname: Luo – volume: 48 start-page: 7445 year: 2005 ident: 2021112213074206800_B26 article-title: Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes publication-title: J. Med. Chem. doi: 10.1021/jm050607w contributor: fullname: VanBrocklin – volume: 110 start-page: 763 year: 2002 ident: 2021112213074206800_B15 article-title: Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α publication-title: Cell doi: 10.1016/S0092-8674(02)00940-6 contributor: fullname: Garrett – volume: 11 start-page: 600 year: 2005 ident: 2021112213074206800_B29 article-title: Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.600.11.2 contributor: fullname: Zhang – volume: 5 start-page: 341 year: 2005 ident: 2021112213074206800_B2 article-title: ERBB receptors and cancer: the complexity of targeted inhibitors publication-title: Nat. Rev. Cancer doi: 10.1038/nrc1609 contributor: fullname: Hynes – volume: 23 start-page: 273 year: 2005 ident: 2021112213074206800_B14 article-title: Phe45 of NRG2β is critical for the affinity of NRG2β for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2β publication-title: Growth Factors doi: 10.1080/08977190500199345 contributor: fullname: Hobbs – volume: 102 start-page: 7665 year: 2005 ident: 2021112213074206800_B10 article-title: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.0502860102 contributor: fullname: Kwak – volume: 23 start-page: 1428 year: 2004 ident: 2021112213074206800_B33 article-title: Gene expression profiling of ErbB receptor and ligand-dependent transcription publication-title: Oncogene doi: 10.1038/sj.onc.1207257 contributor: fullname: Amin |
SSID | ssj0014040 |
Score | 1.947633 |
Snippet | The EGFR (epidermal growth factor receptor; ErbB1) is frequently the subject of genetic changes in human tumours which contribute to the malignant phenotype by... |
SourceID | pubmedcentral crossref |
SourceType | Open Access Repository Aggregation Database |
StartPage | 79 |
Title | The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2β and agonist-independent coupling with downstream signalling events |
URI | https://pubmed.ncbi.nlm.nih.gov/PMC1450006 |
Volume | 396 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEBVJLu2l5KOl-WSgpaQHZdeyJNvHZMk2BFJK2kBui2VLG8Nau2S9h_1LOeaH5DdlRmun3WtvBtlgPDOaeePRe4x9xbRjlSskd6rvuMRo4mlmDc-dUwadqu8SOu9881Nf3cnre3W_wVR3FiYM7RemOvOT-sxXD2G2clYXvW5OrPfrZhBJovHXvU22mcRxB9HbXweyL9vGiuQaM1jHSSpF7-KaeiiRToP0HlYCGO1qLSGtD0b-k2mG2-xDWyLC-epVdtiG9bts79wjPK6X8A3C0Gbohu-yd4NOsG2PPaHJwZLiK262ExgjwG4eYCWoA7ix2RldnF7-GN5-57-lFEOoFyQiDGU1n03y5RwqT0Xk3JaAX7HCaF8CFrVApJekWV95Ll6eIfe4Pp4S5y6v3mR0GyimCzrfOwZq7kJJfWuaY6-BhkTyQP4NgTBq_pHdDS__DK54K8XAC4z4hmdEXeewFurrUhWpMIlLTO4QPWqjCMbJ0sWRcEZnRuvcEQmMLa3N0lQaRDDxJ7blp95-ZoCQW5g8koVAKFPGRaYsFhUiMpk06Ddmn33p7DGarRg3RuFPuRSjvwbcZ8maqd5uJbrs9RX0okCb3XrNwX8_ecjerxowikfqiG01jwt7jCVJY06CC74ChTblOA |
link.rule.ids | 230,315,733,786,790,891,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Bb9MwFLbGOIwLjA20DQZPAiE4uG1cO02Oo1opY50QbGi3KnbsLqJJqzU9lJ_EkR-y37T3nGRQbnCL5FhK5Of33vf8-XuMvcawY5UzkjvVcVzibuJRbDVPnFMajarjenTfeXQWDi_kyaW63GCquQvjSftGZ61imreK7MpzK-e5aTc8sfbnUT-QJOMftu-x-7hfhWpAen14IDuyLq1IHmIMa1RJpWi_P6EqShBGvvke5gI4X62FpHVq5B-xZvCIfWu-sqKYfG8tS90yP_4ScPzn39hmD-vsE46q4cdswxY7bPeoQOSdr-ANeD6oL7TvsK1-0wtul_1EawJLzWTRj09hgti9vIKqVw-gz7Rzenh7_GHw5R3_KqUYQL6k_sSQZov5NFktICsoP13YFHCBMnQkK8B8GUhP006IDs_FzS9IChyfzEjOl2d3HXpLMLMlXR2eANWNIaWSOFHkcyD-SeJ1xcFrUS2esIvB8Xl_yOsuD9ygMyl5TKp4DtOsTpgqEwndcz2dOASmoVaEEGXquoFwOox1GCaO9GVsam0cRVIjOOo-ZZvFrLB7DBDNC50E0ghESWnXxMpiviICHUuNJqn32atmocfzSsxj7A_hpRj_tox91luzgbtXSYl7fQRX1ity1yt58N8zX7Kt4fnodHz68ezTM_agqvMoHqjnbLO8XtpDzHxK_cLb-S1HdQct |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLWgSMCmQAui5XUlEIKFJxOPnceyDA2l0KoCKlXdjOLEnkZMMhGTWQyfxJIP4Zu410lKh2V3kWxLiXx9Xzk-h7FXGHaMspnkVg0tl3iaeBQbzVNrlUajGtqQ7jsfHQcHp_LwTJ1dkfpyoP1MF4NqVg6q4sJhK-sy83qcmHdyNPYl0fgHXp1b7ya7hWdWhH2h3v1AkEPZtVckDzCO9cykUnjvDqmT4geRE-DDfADXq7WwtA6PvBJvknvsvH_TFmbyfbBs9CD7-R-J47U-5T7b7LJQ2GunPGA3TLXFtvcqrMDLFbwGhwt1Dfctdmfca8Jts19oVWBIVBb9-QymWMM3F9Bq9gD6TlPTw5v9D8mXt_yrlCKBckk6xZAXi3qWrhZQVJSnLkwOuFEFOpQVYN4MxKtppgSL5-LPb0grHJ_OidaXF5dKvQ1k8yVdIZ4C9Y8hp9Y4QeVLIBxK6vjFwXFSLR6y02T_2_iAd2oPPEOn0vCY2PEsplvDIFdZJHRoQ51aLFADrahSlLkd-cLqINZBkFrimTG5MXEUSY1F0ugR26jmlXnMAKt6oVNfZgKrpXyUxcpg3iJ8HUuNpql32Mt-syd1S-oxcT_jpZj8s44dFq7ZweVUYuReH8Hddczc3W7uXnvlC3b75H0y-fzx-NMTdrdt9yjuq6dso_mxNM8wAWr0c2fqfwFrfwmt |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+epidermal+growth+factor+receptor+%28EGFR%29-S442F+mutant+displays+increased+affinity+for+neuregulin-2%CE%B2+and+agonist-independent+coupling+with+downstream+signalling+events&rft.jtitle=Biochemical+journal&rft.au=Gilmore%2C+Jennifer%C2%A0L.&rft.au=Gallo%2C+Richard%C2%A0M.&rft.au=Riese%2C+David%C2%A0J.&rft.date=2006-05-15&rft.pub=Portland+Press+Ltd&rft.issn=0264-6021&rft.eissn=1470-8728&rft.volume=396&rft.issue=Pt+1&rft.spage=79&rft.epage=88&rft_id=info:doi/10.1042%2FBJ20051687&rft_id=info%3Apmid%2F16445385&rft.externalDBID=PMC1450006 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0264-6021&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0264-6021&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0264-6021&client=summon |